. 2019 Sep 3;2019(9):CD011749. doi: 10.1002/14651858.CD011749.pub2

Summary of findings 2. Days with coma.

Outcome: days with coma
Patient or population: critically ill adult with confirmed or at high risk of delirium  Settings: intensive care units in Australia and New Zealand, Canada, Egypt, Netherlands, Turkey, USA, UK  Intervention: any pharmacological intervention Control: placebo or active comparator
Comparisons	*Illustrative comparative risks (95% CI)**		Ratio of means (RoM) based on log RoM estimates from meta‐analysis (IV, random, 95% CI)	Number of participants  (studies)	Quality of the evidence  (GRADE) based on NMA	NMA results   (assuming  consistency equations)
	Assumed risk	Corresponding risk based on NMA estimates
	Placebo/Comparator	Intervention drug
Typical antipsychotic vs placebo	Median number of days with coma: 1 to 2 days for placebo	1.53 days with coma (95% CrI 0.86 to   2.57) corresponding to 2 days in the placebo group	RoM: exp(‐0.29) = 0.75 (95% CI 0.49 to 1.13);  log RoM: ‐0.29 (‐0.71 to 0.12); I² = 74%	588  (3 studies)	⊕⊕⊝⊝  Low^a,b	RoM (95% CrI): 0.77   (0.43 to 1.29),   SUCRA = 0.820, mean Pr(best) = 0.620, mean rank = 1.54
Atypical antipsychotic vs placebo	Median number of days with coma: 1 to 2 days for placebo	1.88 days with coma (95% CrI 0.96 to   3.43) corresponding to 2 days in the placebo group	RoM: exp(0.06) = 1.06 (95% CI 0.88 to 1.30);  log RoM: 0.06 (‐0.13 to 0.26); I² = 0%	440  (2 studies)	⊕⊕⊕⊝  Moderate^b	RoM (95% CrI): 0.94   (0.48 to 1.72),   SUCRA = 0.422, mean Pr(best) = 0.132, mean rank = 2.73
Statin (HMG‐CoA) vs placebo	Mean number of days with coma: 1.1 to 4.2 days for placebo	1.84 days with coma (95% CrI 0.98 to   3.59) corresponding to 2 days in the placebo group	RoM: exp(‐0.10) = 0.90 (95% CI 0.73 to 1.12);  log RoM: ‐0.10 (‐0.32 to 0.11); I² = 0%	414  (2 studies)	⊕⊕⊕⊝  Moderate^b	RoM (95% CrI): 0.92   (0.49 to 1.80),   SUCRA = 0.481, mean Pr(best) = 0.222, mean rank = 2.56
The basis for the assumed risk* (e.g. the median control group risk across studies). The corresponding risk (and its 95% CrI) is calculated as the assumed risk multiples the ratio of means (and its 95% CrI) based on NMA.  CI: confidence interval; CrI: credible interval; HMG‐CoA: 5‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor; NMA: network meta‐analysis; Pr(best): probability(best); RoM: ratio of means; SUCRA: surface under the cumulative ranking curve.
GRADE Working Group grades of evidence.  High quality: further research is very unlikely to change our confidence in the estimate of effect.  Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  Very low quality: we are very uncertain about the estimate.

^aDowngraded one level for heterogeneity (I² of 50% to 75%, > 75% considered as medium and large heterogeneity).  ^bDowngraded one level for imprecision (wide credible interval).